GSK (NYSE:GSK) Issues FY 2025 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.090-2.130 for the period, compared to the consensus estimate of 4.520. The company issued revenue guidance of $40.1 billion-$40.9 billion, compared to the consensus revenue estimate of $34.3 billion.

GSK Trading Up 8.0 %

Shares of NYSE:GSK traded up $2.80 during midday trading on Wednesday, reaching $37.64. 8,298,732 shares of the company’s stock were exchanged, compared to its average volume of 4,446,791. The stock has a market cap of $78.02 billion, a price-to-earnings ratio of 24.48, a P/E/G ratio of 1.38 and a beta of 0.64. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm’s 50 day simple moving average is $34.10 and its two-hundred day simple moving average is $37.60. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. As a group, sell-side analysts forecast that GSK will post 3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GSK. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and cut their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.